FOXO1 and type 2 diabetes mellitus: Moreover, Evogliptin (EVO), a dipeptidyl peptidase-4 (DPP-4) inhibitor known for its glucose-lowering effects in T2D, demonstrated the ability to prevent DbCM and associated lipotoxicity by suppressing CD36 protein expression and enhancing the phosphorylation of FoxO1 at Serine 256 position, indicative of its inactivation, in db/db mice [49].